When evaluated against ovarian cancer, nobiletin reduced VEGF expression by inhibiting AKT activation, thereby reducing angiogenesis and inhibiting tumor proliferation (Chen et al., 2015). This evidence concerns the gene AKT1 and ovarian cancer.